Join
Live feed
·
PRReleasevia Quantisnow
GSK plc logo
Summit Therapeutics Inc. logo

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

ByQuantisnow·Wall Street's wire, on your screen.
GSK· GSK plcSMMT· Summit Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GSK (GSK plc), SMMT (Summit Therapeutics Inc.) and more on Quantisnow.

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) | Quantisnow